搜索筛选:
搜索耗时1.3090秒,为你在为你在102,285,761篇论文里面共找到 66 篇相符的论文内容
发布年度:
[期刊论文] 作者：Mei Ai CAO,Xiao Bai SUN,Pei Hu,
来源：中国化学快报（英文版） 年份：2006
为探究吕家坨井田地质构造格局,根据钻孔勘探资料,采用分形理论和趋势面分析方法,研究了井田7...
QUANTIFICATION OF A NEW ANTITUMOR AGENT ICOTINIB IN RAT MICROSOMAL INCUBATIONS USING LIQUID CHROMATO
[会议论文] 作者：Xin ZHENG,Qian ZHAO,Ji JIANG,Pei HU,
来源：2009第十三届北京分析测试学术报告会 年份：2009
...
Calcium absorption from calcium fortified soymilk and cows milk in postmenopausal Chinese women with
[会议论文] 作者：Warren T.K.Lee,Ji Jiang,X.J.Lai,Pei Hu,H.Y.Wang,
来源：International Conference on Osteoporosis and Bone Research 2 年份：2008
...
QUANTIFICATION OF A NEW ANTITUMOR AGENT ICOTINIB IN RAT MICROSOMAL INCUBATIONS USING LIQUID CHROMATO
[会议论文] 作者：Xin ZHENG,Qian ZHAO,Ji JIANG,Pei HU,
来源：2009第十三届北京分析测试学术报告会 年份：2009
...
Predictions about probabilities of adverse events and appropriate dose of roflumilast for Chinese CO
[会议论文] 作者：Xinge Cui,Xin Zheng,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
...
Population pharmacokinetic pharmacodynamics model for PEGylated human growth hormone in healthy subj
[会议论文] 作者：Xin Zheng,Xia Chen,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
...
Application of population pharmacokinetic modeling in clinical development of a novel PPI CPRCX: com
[会议论文] 作者：Xuemei Liu,Hongyun Wang,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
...
Prediction of First-in-Human Dose of CPRC1 Using Allometric Scaling, IVIVE and PK/PD Modeling Method
[会议论文] 作者：Yang Liu,Dongyang Liu,Ji Jiang,Pei Hu,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Diabetes mellitus is one of the most common chronic disease in the world, CPRC 1 is a novel dipeptidylpeptidase-Ⅳ(DPP-4) inhibitor which was proposed to control hyperglycemia in patients with type 2 d...
Application of population pharmacokinetic modeling in clinical development of a novel PPI CPRCX: com
[会议论文] 作者：Xuemei Liu,Hongyun Wang,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
CPRCX is a novel investigated proton pump inhibitor, which shows dramatic success in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper f...
Population pharmacokinetic pharmacodynamics model for PEGylated human growth hormone in healthy subj
[会议论文] 作者：Xin Zheng,Xia Chen,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
Background: Growth hormone deficiency (GHD) in paediatric and adult patients so currently necessitates long-term treatment and persistence with a daily s.c injection regimen.Taking the low compliance...
Predictions about probabilities of adverse events and appropriate dose of roflumilast for Chinese CO
[会议论文] 作者：Xinge Cui,Xin Zheng,Pei Hu,Ji Jiang,
来源：第五届定量药理学与新药评价国际会议 年份：2015
Backgrounds: Roflumilast is an oral inhibitor of phosphodiesterase 4(PDE4), which is mainly metabolized by CYP3A4 and CYP1A2.The main metabolite of it is roflumilast N-oxide, which contributes to the...
,Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of mid
[期刊论文] 作者：Hong-yun WANG,Xia CHEN,Ji JIANG,Jun SHI,Pei HU,
来源：中国药理学报（英文版） 年份：2016
...
OBSERVATIONS OF PLASMA ARGININE,ADMA AND SDMA CONCENTRATIONS IN RELATION TO RENAL FUNCTION IN BURN P
[会议论文] 作者：Hongyun WANG,Ji JIANG,Pei HU,Yongming YU,Ronald G.TOMPKINS,
来源：2009第十三届北京分析测试学术报告会 年份：2009
...
Predicting whole blood concentrations of zonisamide in human using a physiologically based pharmacok
[会议论文] 作者：Xin Zheng,Kairui Feng,Pei Hu,Ji Jiang,Jun Shi,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium 年份：2013
...
OBSERVATIONS OF PLASMA ARGININE,ADMA AND SDMA CONCENTRATIONS IN RELATION TO RENAL FUNCTION IN BURN P
[会议论文] 作者：Hongyun WANG,Ji JIANG,Pei HU,Yongming YU,Ronald G.TOMPKINS,
来源：2009第十三届北京分析测试学术报告会 年份：2009
...
Development and validation a PBPK model to predict age-dependent PK for Chinese subjects-a case stud
[会议论文] 作者：Hongyun Wang,Xia Chen,Jun Shi,Ji Jiang,Pei Hu,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Aim:Todevelop and validate a general physiologicallybased pharmacokinetic (PBPK) model for hepatic pathway in Chinese adults at various ages, and to evaluate it with midazolam (substrate of CYP3A4) as...
[会议论文] 作者：Jia Chen,Dongyang Liu,Qian Zhao,Ji Jiang,Pei Hu,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Objective:Icotinib is a potent small-molecule inhibitor of epidermal growth factor receptor (EGFR)-tyrosine kinase (TKI), which was designed for the treatment of non-small cell lung cancer (NSCLC).It...
A semi-mechanistic population pharmacokinetic model describing the time-dependent kinetics of Red Bl
[会议论文] 作者：Kairui Feng,Xin Zheng,Wenyuan Qi,Pei Hu,Ji Jiang,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Background: XQ (Carfree, Nanjing, China), a new chemical entity that possesses pharmacological activity on PlateletActivating Factor (PAF).XQ was approved into phase Ⅰ evaluation for treatment of isch...
A Mechanistic Pharmacokinetic-Pharmacodynamic Model for the Effect of Esomeprazole in Healthy Subjec
[会议论文] 作者：Dongyang Liu,Hong Yang,Jiaming Qian,Ji Jiang,Pei Hu,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Esomeprazole has proved to be effective for the treatment of gastroesophogeal reflux disease (GERD) and ulcers, where intra-gastric pH value is a biomarker to indicate esomeprazole effects on these di...
Population pharmacokinetic/pharmacodynamic Modeling for Pegylated Recombinant Human Growth Hormone (
[会议论文] 作者：Xin Zheng,Tao Liu,Qian Zhao,Pei Hu,Ji Jiang,
来源：第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu 年份：2013
Objective:CPRC-Y is a pegylatedrecombinant human growth hormone (rhGH) developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration.T...
相关搜索：
